systemic mastocytosis
Information
- Disease name
- systemic mastocytosis
- Disease ID
- DOID:349
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04681105 | Active, not recruiting | Phase 1 | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | November 18, 2020 | May 5, 2026 |
| NCT00171912 | Completed | Phase 2 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | September 2004 | January 2012 |
| NCT00449748 | Completed | Phase 2 | Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis | April 2007 | October 2009 |
| NCT00493129 | Completed | Phase 2 | Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | July 2004 | August 2007 |
| NCT00109707 | Completed | Phase 1/Phase 2 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | April 2005 | September 2012 |
| NCT01297777 | Completed | Phase 4 | Imatinib in KIT-negative Systemic Mastocytosis | January 2011 | August 2015 |
| NCT01334996 | Completed | Use of Tamoxifen in Systemic Mastocytosis | February 2005 | August 28, 2019 | |
| NCT01807598 | Completed | Phase 2 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | September 2013 | September 2017 |
| NCT02441166 | Completed | N/A | Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis | October 6, 2015 | July 2019 |
| NCT02478957 | Completed | Phase 2 | Treatment of Indolent Systemic Mastocytosis With PA101 | June 2015 | June 2016 |
| NCT03401060 | Completed | Phase 3 | Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis | March 5, 2018 | March 11, 2024 |
| NCT00918931 | Terminated | Phase 2 | Obatoclax for Systemic Mastocytosis | June 2009 | October 2010 |
| NCT03214666 | Terminated | Phase 1/Phase 2 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | January 1, 2020 | September 29, 2021 |
| NCT02415608 | Terminated | Phase 2 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | March 2015 | June 14, 2017 |
| NCT00979160 | Unknown status | Phase 2 | Evaluation of Response of Dasatinib to Treat Mastocytosis | November 2009 | December 2012 |
| NCT01602939 | Unknown status | Phase 2/Phase 3 | Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis | May 2012 | June 2017 |
| NCT03739606 | Withdrawn | Phase 2 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | October 20, 2020 | October 20, 2020 |
- Disase is a (Disease Ontology)
- DOID:350
- Cross Reference ID (Disease Ontology)
- GARD:8616
- Cross Reference ID (Disease Ontology)
- ICD10CM:D47.02
- Cross Reference ID (Disease Ontology)
- MESH:D034721
- Cross Reference ID (Disease Ontology)
- NCI:C9235
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:123310005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0221013
- Exact Synonym (Disease Ontology)
- SMCD - systemic mast cell disease
- Exact Synonym (Disease Ontology)
- systemic tissue mast cell disease
- OrphaNumber from OrphaNet (Orphanet)
- 2467